Explore Mirati through 10+ example sentences from English. Ideal for language learners, writers and word enthusiasts.
Mirati in a sentence
Using Mirati
- In the example corpus, mirati often appears in combinations such as: mirati therapeutics, of mirati, that mirati.
Context around Mirati
- Average sentence length in these examples: 21.5 words
- Position in the sentence: 6 start, 14 middle, 0 end
- Sentence types: 20 statements, 0 questions, 0 exclamations
Corpus analysis for Mirati
- In this selection, "mirati" usually appears in the middle of the sentence. The average example has 21.5 words, and this corpus slice is mostly made up of statements.
- Around the word, downgraded, beats, upgraded and therapeutics stand out and add context to how "mirati" is used.
- Recognizable usage signals include shares of mirati therapeutics by and expect that mirati therapeutics inc. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "mirati" sits close to words such as aaj, abn and aboriginals, which helps place it inside the broader word index.
Example types with mirati
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
Deutsche Bank assumed coverage on Mirati Therapeutics in a report on Thursday, July 18th. (14 words)
Ophthotech beats Mirati Therapeutics on 7 of the 13 factors compared between the two stocks. (15 words)
Quadrant Capital Group LLC raised its stake in Mirati Therapeutics by 161.6% in the second quarter. (17 words)
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat. (33 words)
Credit Suisse Group set a $115.00 price objective on Mirati Therapeutics and gave the stock a “buy” rating in a research report on Friday, September 27th. (27 words)
HC Wainwright reiterated a “buy” rating and set a $117.00 price target on shares of Mirati Therapeutics in a research note on Tuesday, August 6th. (26 words)
Example sentences (20)
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.
As a group, equities analysts expect that Mirati Therapeutics, Inc. will post -13.5 earnings per share for the current year.
Finally, Great West Life Assurance Co. Can purchased a new stake in Mirati Therapeutics in the third quarter worth approximately $145,000.
MetLife Investment Management LLC purchased a new position in shares of Mirati Therapeutics in the 1st quarter valued at about $197,000.
Mirati Therapeutics shares are currently trading at above $42, and are down by almost 4% year-to-date, bringing their one-year return to -46%.
Quadrant Capital Group LLC boosted its position in shares of Mirati Therapeutics by 161.6% during the 2nd quarter.
Quadrant Capital Group LLC raised its stake in Mirati Therapeutics by 161.6% in the second quarter.
Leerink Partnrs downgraded Mirati Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 7th.
Mirati Therapeutics, Inc, a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States.
Credit Suisse Group set a $115.00 price objective on Mirati Therapeutics and gave the stock a “buy” rating in a research report on Friday, September 27th.
Deutsche Bank assumed coverage on Mirati Therapeutics in a report on Thursday, July 18th.
Equities research analysts forecast that Mirati Therapeutics Inc will post -5.04 earnings per share for the current fiscal year.
Finally, GAM Holding AG bought a new position in Mirati Therapeutics during the third quarter valued at about $236,000.
Finally, OppenheimerFunds Inc. grew its stake in shares of Mirati Therapeutics by 0.4% during the 1st quarter.
HC Wainwright reiterated a “buy” rating and set a $117.00 price target on shares of Mirati Therapeutics in a research note on Tuesday, August 6th.
Metropolitan Life Insurance Co NY boosted its position in shares of Mirati Therapeutics by 6.5% during the 1st quarter.
Ophthotech beats Mirati Therapeutics on 7 of the 13 factors compared between the two stocks.
Zacks Investment Research upgraded Mirati Therapeutics from a sell rating to a hold rating in a research report on Thursday, October 4th.
As a group, equities research analysts expect that Mirati Therapeutics Inc will post -3.12 earnings per share for the current year.
Quantitative Systematic Strategies LLC acquired a new stake in shares of Mirati Therapeutics during the 2nd quarter valued at approximately $214,000.
Common combinations with mirati
These word pairs occur most frequently in English texts:
- mirati therapeutics 22×
- of mirati 6×
- that mirati 3×
- in mirati 3×
- for mirati 2×
- on mirati 2×